This website isn’t supported by Internet Explorer. We recommend that you use a different browser (e.g. Edge, Chrome, Firefox, Safari, or similar) for the best experience of our content.

For healthcare professionals only

You are viewing the Novo Nordisk Virtual platform, provided to non-US health care professionals from around the world. By accessing this site and materials you accept this legal notice and expressly confirm your status as a healthcare professional.

 

This site is not country-specific and therefore may contain information which is not applicable to your country. Therefore, before prescribing any product, always refer to local materials such as the prescribing information and/or the Summary of Product Characteristics.

 

This site is not intended to provide medical advice and/or treatment guidance. Novo Nordisk accepts no liability for the accuracy, completeness or use of the information, and disclaims any liability to update the information contained on this site.

I hereby declare I am a non-US health care professional and that I have read and agreed to the terms mentioned above.

Supporting healthy eating patterns is fundamental in diabetes treatment, with management of dietary quality and energy restriction being core dimensions for improving glycemic control.

 

Applying a person-centered approach to identify healthy dietary habits can help patients achieve a new energy deficit, leading to weight loss and additional health benefits.1

Significant improvements to HbA1c and cardiometabolic health can be achieved by increasing physical activity level.

 

Patients should be encouraged to ≥150 min of moderate-intensity physical activity or ≥75 min vigorous-intensity activity per week, but an increase of as little as 500 steps a day can decrease the all-cause mortality rates and risk of cardiovascular morbidity with 2-9%.1

People living with type 2 diabetes often suffer from sleep disorders, which are associated with an increased risk of obesity and impairments in daily functioning. Studies show that more than half of people living with type 2 diabetes are affected by obstructive sleep apnea, which is associated with blood glucose levels.1

Empower your patients to look at food in new ways. Here are 3 methods that can help establish healthy and maintainable eating habits.

Are your patients looking for inspiration to manage their diabetes through exercise? These useful tips on how to get moving might help your patients’ set realistic goals.

Good quality sleep improves general health and well-being for people with diabetes.1 This guide may help your patients improve their bedtime routine.
icon_calendar_blue

 

Still not under control? 

Scroll down to see recommendations for glucose-lowering medications when patients are not controlled through diet and exercise management.

icon_calendar_blue

 

Still not under control? 

Scroll down to see recommendations for glucose-lowering medications when patients are not controlled through diet and exercise management.

Oral tablet or injection

 

  • Mode of action: Increases insulin release when blood glucose increases, reduces glucose release from the liver, delays gastric emptying and increases satiety
  • Beneficial characteristics: Promotes weight loss, proven CV benefits (*)
  • Common side-effects: Gastrointestinal such as nausea and diarrhea
  • Caution: Not suited for patients with previous pancreatitis

*according to label indication

Oral tablet

 

  • Mode of action: Increasing glucose excretion in the urine by preventing reabsorption of glucose from the kidneys
  • Beneficial characteristics: Reduced blood pressure and weight loss, proven CV benefits (*)
  • Common side-effects: Urinary and genital infections
  • Caution: May not be suited for patients with kidney disease

*according to label indication

Oral tablet or injection

 

  • Mode of action: Increases insulin release when blood glucose increases, reduces glucose release from the liver, delays gastric emptying and increases satiety
  • Beneficial characteristics: Promotes weight loss, proven CV benefits*
  • Common side-effects: Gastrointestinal such as nausea and diarrhea
  • Caution: Not suited for patients with previous pancreatitis

*according to label indication

Oral tablet

 

  • Mode of action: Increasing glucose excretion in the urine by preventing reabsorption of glucose from the kidneys
  • Beneficial characteristics: Reduced blood pressure and weight loss, proven CV benefits*
  • Common side-effects: Urinary and genital infections
  • Caution: May not be suited for patients with kidney disease

*according to label indication

 

 

 

If your patients are in need for further intensification following 2nd-line therapy, or if you'd like to understand the underlying rationale for the decisions and guidance for the management of type 2 diabetes, please refer to the EASD/ADA consensus report.

GLP-1 RA education

Learn more about GLP-1 RA as a second-line treatment for people living with type 2 diabetes.
Patient profiles

Making the best choice for your patient means tackling type 2 diabetes from different angles. Explore the patient cases to see which patients could benefit from a Shift?

Making the best choice for your patient means tackling type 2 diabetes from different angles. Explore the patient cases to see which patients could benefit from a Shift?

1.

Davies MJ, Aroda VR, Collins BS, et al. Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2022 Nov 1;45(11):2753-2786.

2.

Buse JB, Wexler D, Tsapas A et al. 2019 Update to: Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2020;43(2):487-493.

3.

Mosenzon O, Alguwaihes A, Leon JLA, et al. CAPTURE: a multinational, cross-sectional study of cardiovascular disease prevalence in adults with type 2 diabetes across 13 countries. Cardiovasc Diabetol. 2021 Jul 27;20(1):154.